GERON CORPORATION
10-Q, EX-27.1, 2000-08-14
PHARMACEUTICAL PREPARATIONS
Previous: GERON CORPORATION, 10-Q, 2000-08-14
Next: KRONOS INC, 10-Q, 2000-08-14



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                          74,365
<SECURITIES>                                       999
<RECEIVABLES>                                      485
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                76,103
<PP&E>                                          10,267
<DEPRECIATION>                                 (6,820)
<TOTAL-ASSETS>                                 119,333
<CURRENT-LIABILITIES>                            8,266
<BONDS>                                         31,344
                                0
                                          0
<COMMON>                                            22
<OTHER-SE>                                      66,660
<TOTAL-LIABILITY-AND-EQUITY>                   119,333
<SALES>                                              0
<TOTAL-REVENUES>                                 3,047
<CGS>                                                0
<TOTAL-COSTS>                                   18,592
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              11,752
<INCOME-PRETAX>                               (24,999)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (24,999)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (24,999)
<EPS-BASIC>                                   (1.24)
<EPS-DILUTED>                                   (1.24)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission